AACE Pharma slammed with FDA warning letter for contract manufacturer's shortfalls - Fierce Pharma
AACE Pharma received an FDA warning letter due to shortfalls in its contract manufacturing practices, highlighting compliance issues with cGMP standards.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 2, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. All contract manufacturers and pharmaceutical companies working with AACE Pharma. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediate action required; no specific deadline stated.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA issued a warning letter citing non-compliance with good manufacturing practices (cGMP).
Who it affects
All contract manufacturers and pharmaceutical companies working with AACE Pharma.
What you must do
Review and rectify compliance issues as per FDA guidelines to avoid further penalties.
Deadline
Immediate action required; no specific deadline stated.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- The FDA just cleared the way for drug importation. What now? - politico.com
- EPA names BD, Edwards and Medtronic on list of higher-risk sterilization facilities - MedTech Dive
- COVID-19 vaccines may be harder to get in Kentucky under new FDA guidelines. Here's why - The Courier-Journal
- Greek national indicted for selling counterfeit and unapproved prescription drugs to internet pharmacies and undercover agents - justice.gov
- Pfizer Kansas plant hit by FDA 483 with 8 repeat observations - bioprocessintl.com